ArticleClinical endocrinology2026
ThyroidPrint: Thyroid Genetic Classifier Long-Term Follow-Up of Benign Called Lesions.
Article in Clinical endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ThyroidPrint: Thyroid Genetic Classifier Long-Term Follow-Up of Benign Called Lesions.Clinical endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe management of indeterminate thyroid nodules (ITNs) remains challenging, with molecular classifiers emerging as valuable tools for risk stratification. ThyroidPrint is a novel quantitative PCR-based 10-gene classifier designed to predict benignity in ITNs, enabling more informed clinical decision-making.
objectiveTo evaluate the long-term follow-up (≥ 5 years) of patients with a benign ThyroidPrint result managed via active surveillance, assessing the safety, durability and clinical utility of the test in a real-world setting.
methodsThis prospective, single-centre study included 104 patients with indeterminate cytology (Bethesda III/IV) and a previous benign ThyroidPrint result, followed for a median of 5.3 years. Ultrasound monitoring and clinical assessments guided management, with surgery reserved for significant nodule growth or patient preference. Outcomes included the proportion of patients remaining under surveillance, nodule growth and surgical pathology.
resultsOf the 104 patients with benign ThyroidPrint results, 94.2% remained under active surveillance at 5 years, with only 5.8% undergoing surgery, all of which confirmed benign or low-risk histology. The false-negative rate was minimal among resected nodules supports the test's safety as a rule-out tool. Ultrasonographic monitoring proved effective for early detection of changes in warranting intervention.
conclusionsLong-term follow-up demonstrates that ThyroidPrint provides a reliable, safe and durable approach to managing ITN, significantly reducing unnecessary surgeries while maintaining a low rate of missed malignancies. These findings reinforce its role in personalised patient management and support structured surveillance protocols for selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.